Antonio Omuro, MD

• Ajay Malhotra
• David A. Hafler
• Harlan Krumholz
• Harriet Kluger
• James Duncan
• James E. Hansen
• Lawrence Staib
• Lucia Jilaveanu
• Mariam Aboian
• Pallavi Gopal
• Patricia LoRusso
• Richard Bronen
• Roy S. Herbst
• Sacit Bulent Omay
• Sam Payabvash
• Sanjay Aneja
• Silvio Inzucchi
• Veronica Chiang
• Zeynep Erson Omay

Glioblastoma; Meningeal Neoplasms; Clinical Trial; Central Nervous System Neoplasms

• Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer ImagingJoel M, Avesta A, Yang D, Zhou J, Omuro A, Herbst R, Krumholz H, Aneja S. Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging Cancers 2023, 15: 1548. PMID: 36900339, PMCID: PMC10000732, DOI: 10.3390/cancers15051548.
• Top advances of the year: Neuro‐oncologyBarden M, Omuro A. Top advances of the year: Neuro‐oncology Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.
• Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant GliomaFanucci K, Pilat M, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman F, Gonzalez J, Giglio P, Ivy S, Bindra R, Omuro A, LoRusso P. Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant Glioma Cancer Research Communications 2023, 3: 192-201. DOI: 10.1158/2767-9764.crc-22-0436.
• Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant GliomaFanucci K, Pilat M, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman F, Gonzalez J, Giglio P, Ivy S, Bindra R, Omuro A, LoRusso P. Multicenter Phase 2 Trial of the PARP Inhibitor Olaparib in Recurrent IDH1 and IDH2-Mutant Glioma Cancer Research Communications 2023, 3: 192-201. PMID: 36968138, PMCID: PMC10035510, DOI: 10.1158/2767-9764.crc-22-0436.
• NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NETJekel L, Bousabarah K, Lin M, Merkaj S, Kaur M, Avesta A, Aneja S, Omuro A, Chiang V, Scheffler B, Aboian M. NIMG-02. PACS-INTEGRATED AUTO-SEGMENTATION WORKFLOW FOR BRAIN METASTASES USING NNU-NET Neuro-Oncology 2022, 24: vii162-vii162. PMCID: PMC9661012, DOI: 10.1093/neuonc/noac209.622.
• NIMG-20. INCORPORATION OF AI-BASED AUTOSEGMENTATION AND CLASSIFICATION INTO NEURORADIOLOGY WORKFLOW: PACS-BASED AI TO BUILD YALE GLIOMA DATASETLost J, Tillmans N, Merkaj S, von Reppert M, Lin M, Bousabarah K, Huttner A, Aneja S, Omuro A, Aboian M, Avesta A. NIMG-20. INCORPORATION OF AI-BASED AUTOSEGMENTATION AND CLASSIFICATION INTO NEURORADIOLOGY WORKFLOW: PACS-BASED AI TO BUILD YALE GLIOMA DATASET Neuro-Oncology 2022, 24: vii165-vii166. DOI: 10.1093/neuonc/noac209.638.
• Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.Fanucci K, Pilat M, Shah R, Boerner S, Li J, Durecki D, Drappatz J, Collichio F, Puduvalli V, Lieberman F, Gonzalez J, Giglio P, Bao X, Ivy S, Bindra R, Omuro A, LoRusso P. Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma. Journal Of Clinical Oncology 2022, 40: 2035-2035. DOI: 10.1200/jco.2022.40.16_suppl.2035.
• Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoterLim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter Neuro-Oncology 2022, 24: 1935-1949. PMID: 35511454, PMCID: PMC9629431, DOI: 10.1093/neuonc/noac116.
• Immune-checkpoint inhibitors for glioblastoma: what have we learned?Omuro A. Immune-checkpoint inhibitors for glioblastoma: what have we learned? Arquivos De Neuro-Psiquiatria 2022, 80: 266-269. PMID: 35976319, PMCID: PMC9491432, DOI: 10.1590/0004-282x-anp-2022-s129.
• Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialOmuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial Neuro-Oncology 2022, 25: 123-134. PMID: 35419607, PMCID: PMC9825306, DOI: 10.1093/neuonc/noac099.
• Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias AssessmentPetersen G, Shatalov J, Verma T, Brim WR, Subramanian H, Brackett A, Bahar RC, Merkaj S, Zeevi T, Staib LH, Cui J, Omuro A, Bronen RA, Malhotra A, Aboian MS. Machine Learning in Differentiating Gliomas from Primary CNS Lymphomas: A Systematic Review, Reporting Quality, and Risk of Bias Assessment American Journal Of Neuroradiology 2022, 43: 526-533. PMID: 35361577, PMCID: PMC8993193, DOI: 10.3174/ajnr.a7473.
• Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in OncologyJoel MZ, Umrao S, Chang E, Choi R, Yang DX, Duncan JS, Omuro A, Herbst R, Krumholz HM, Aneja S. Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology JCO Clinical Cancer Informatics 2022, 6: e2100170. PMID: 35271304, PMCID: PMC8932490, DOI: 10.1200/cci.21.00170.
• Machine Learning Applications for Differentiation of Glioma from Brain Metastasis—A Systematic ReviewJekel L, Brim WR, von Reppert M, Staib L, Petersen G, Merkaj S, Subramanian H, Zeevi T, Payabvash S, Bousabarah K, Lin M, Cui J, Brackett A, Mahajan A, Omuro A, Johnson MH, Chiang VL, Malhotra A, Scheffler B, Aboian MS. Machine Learning Applications for Differentiation of Glioma from Brain Metastasis—A Systematic Review Cancers 2022, 14: 1369. PMID: 35326526, PMCID: PMC8946855, DOI: 10.3390/cancers14061369.
• Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143 Neuro-Oncology Advances 2022, 4: vdac025. PMID: 35402913, PMCID: PMC8989388, DOI: 10.1093/noajnl/vdac025.
• Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance) Neuro-Oncology Advances 2022, 4: vdac041. PMID: 35664553, PMCID: PMC9154335, DOI: 10.1093/noajnl/vdac041.
• Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgeryPetersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery Neuro-Oncology Advances 2022, 4: vdac116. PMID: 36043121, PMCID: PMC9412827, DOI: 10.1093/noajnl/vdac116.
• Identifying clinically applicable machine learning algorithms for glioma segmentation: recent advances and discoveriesTillmanns N, Lum AE, Cassinelli G, Merkaj S, Verma T, Zeevi T, Staib L, Subramanian H, Bahar RC, Brim W, Lost J, Jekel L, Brackett A, Payabvash S, Ikuta I, Lin M, Bousabarah K, Johnson MH, Cui J, Malhotra A, Omuro A, Turowski B, Aboian MS. Identifying clinically applicable machine learning algorithms for glioma segmentation: recent advances and discoveries Neuro-Oncology Advances 2022, 4: vdac093. PMID: 36071926, PMCID: PMC9446682, DOI: 10.1093/noajnl/vdac093.
• Editorial: Advances in neuro-oncology: stepping in the right direction.Omuro A. Editorial: Advances in neuro-oncology: stepping in the right direction. Current Opinion In Neurology 2021, 34: 825-826. PMID: 34619693, DOI: 10.1097/WCO.0000000000001000.
• CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548Weller M, Lim M, Idbaih A, Steinbach J, Finocchiaro G, Raval R, Ashby L, Ansstas G, Baehring J, Taylor J, Honnorat J, Petrecca K, de Vos F, Wick A, Sumrall A, Roberts M, Slepetis R, Warad D, Lee M, Reardon D, Omuro A. CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 Neuro-Oncology 2021, 23: vi55-vi56. PMCID: PMC8598415, DOI: 10.1093/neuonc/noab196.217.
• CTNI-18. PHASE I AND PRELIMINARY PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB (BGB290) WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMASSchiff D, Bindra R, Li J, Ye X, Ellingson B, Walbert T, Campian J, Nabors L, Lieberman F, Ozer B, Desai A, Omuro A, Wen P, Desideri S, Fisher J, Grossman S. CTNI-18. PHASE I AND PRELIMINARY PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB (BGB290) WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS Neuro-Oncology 2021, 23: vi63-vi63. DOI: 10.1093/neuonc/noab196.243.
• T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapiesJansen JA, Omuro A, Lucca LE. T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies Current Opinion In Neurology 2021, 34: 827-833. PMID: 34569985, PMCID: PMC8595795, DOI: 10.1097/wco.0000000000000988.
• Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment.Tavakoli M, Roghaee S, Gunturu M, Omuro AM, Lam BL, Mendoza-Santiesteban CE. Erdheim-Chester Disease Presenting With Diplopia: A Challenging Diagnosis With Effective Treatment. Journal Of Neuro-ophthalmology : The Official Journal Of The North American Neuro-Ophthalmology Society 2021, 41: e324-e325. PMID: 32956221, DOI: 10.1097/WNO.0000000000001076.
• Comparison of radiomic feature aggregation methods for patients with multiple tumorsChang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.
• A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program.Majersik JJ, Ahmed A, Chen IA, Shill H, Hanes GP, Pelak VS, Hopp JL, Omuro A, Kluger B, Leslie-Mazwi T. A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program. Neurology 2021 PMID: 33931527, DOI: 10.1212/WNL.0000000000012111.
• Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutationsHong CS, Omuro A, An Y, Inzucchi S, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay Z. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations Neuro-Oncology Advances 2021, 3: vdab124-. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
• Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific ApproachesRoque A, Omuro A. Emerging Meningioma Therapies I: Precision Medicine, Targeted Therapies, and Mutation-Specific Approaches 2020, 217-226. DOI: 10.1007/978-3-030-59558-6_14.
• The Role of Medical Therapy for MenigniomasRoque A, Omuro A. The Role of Medical Therapy for Menigniomas 2020, 201-215. DOI: 10.1007/978-3-030-59558-6_13.
• NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASESChang E, Joel M, Chang H, Du J, Yu J, An Y, Hansen J, Omuro A, Chiang V, Aneja S. NIMG-03. DEEP LEARNING SURVIVAL ANALYSIS FOR MULTIPLE BRAIN METASTASES Neuro-Oncology 2020, 22: ii147-ii147. PMCID: PMC7650895, DOI: 10.1093/neuonc/noaa215.616.
• CTNI-50. NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001Wefel J, DeMora L, Gondi V, Tsien C, Chenevert T, Gilbert M, Omuro A, Cao Y, Srinivasan A, Rogers L, Shi W, Nedzi L, Chan M, Suh J, Battiste J, Mishra M, Shivnani A, Movsas B, Mehta M. CTNI-50. NEUROCOGNITIVE FUNCTION (NCF) OF THE PHOTON COHORT IN NRG-BN001 Neuro-Oncology 2020, 22: ii53-ii54. PMCID: PMC7651205, DOI: 10.1093/neuonc/noaa215.216.
• Comparison of Radiomic Feature Aggregation Methods for Patients with Multiple Tumors.Chang E, Joel M, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of Radiomic Feature Aggregation Methods for Patients with Multiple Tumors. MedRxiv : The Preprint Server For Health Sciences 2020 PMID: 33173902, PMCID: PMC7654896, DOI: 10.1101/2020.11.04.20226159.
• Deep Learning Survival Analysis for Brain Metastases Treated with Stereotactic RadiosurgeryChang E, Joel M, Chang H, Du J, Yu J, An Y, Hansen J, Omuro A, Chiang V, Aneja S. Deep Learning Survival Analysis for Brain Metastases Treated with Stereotactic Radiosurgery International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s164-s165. DOI: 10.1016/j.ijrobp.2020.07.932.
• Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001Gondi V, Pugh S, Tsien C, Chenevert T, Gilbert M, Omuro A, Mcdonough J, Aldape K, Srinivasan A, Rogers C, Shi W, Suh J, Algan O, Nedzi L, Chan M, Bahary J, Mehta M. Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001 International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s22-s23. DOI: 10.1016/j.ijrobp.2020.07.2109.
• Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical TrialWang D, Gondi V, Tsien C, Chenevert T, Gilbert M, Omuro A, McDonough J, Aldape K, Cao Y, Srinivasan A, Rogers L, Grimm S, Huang J, Machtay M, Martinez N, Bahary J, Nedzi L, Mehta M, Xiao Y. Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e344-e345. DOI: 10.1016/j.ijrobp.2020.07.822.
• Genetic characterization of an aggressive optic nerve pilocytic gliomaHong CS, Fliney G, Fisayo A, An Y, Gopal PP, Omuro A, Pointdujour-Lim R, Erson-Omay EZ, Omay SB. Genetic characterization of an aggressive optic nerve pilocytic glioma Brain Tumor Pathology 2020, 38: 59-63. PMID: 33098465, PMCID: PMC7585354, DOI: 10.1007/s10014-020-00383-x.
• A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaGilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Neuro-Oncology 2020, 23: noaa240-. PMID: 33085768, PMCID: PMC7992893, DOI: 10.1093/neuonc/noaa240.
• Consolidation Therapy in Primary Central Nervous System LymphomaKim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.
• Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaReardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma JAMA Oncology 2020, 6: 1003-1010. PMID: 32437507, PMCID: PMC7243167, DOI: 10.1001/jamaoncol.2020.1024.
• Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerMalani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.
• Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).Omuro A, DeAngelis L, Karrison T, Bovi J, Rosenblum M, Corn B, Correa D, Wefel J, Aneja S, Grommes C, Schaff L, Waggoner S, Lallana E, Werner-Wasik M, Iwamoto F, Robinson T, Donnelly E, Struve T, Won M, Mehta M. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal Of Clinical Oncology 2020, 38: 2501-2501. DOI: 10.1200/jco.2020.38.15_suppl.2501.
• Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastomaKaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.
• Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicinede la Fuente MI, Rosenblum MK, Diamond EL, Tabar VS, Omuro A. Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine Neurology Neuroimmunology & Neuroinflammation 2020, 7: e686. PMID: 32123043, PMCID: PMC7136060, DOI: 10.1212/nxi.0000000000000686.
• Complications associated with immunotherapy for brain metastases.Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.
• Applications of artificial intelligence in neuro-oncology.Aneja S, Chang E, Omuro A. Applications of artificial intelligence in neuro-oncology. Current Opinion In Neurology 2019, 32: 850-856. PMID: 31609739, DOI: 10.1097/wco.0000000000000761.
• Imaging biomarkers for brain metastases: more than meets the eye.Aneja S, Omuro A. Imaging biomarkers for brain metastases: more than meets the eye. Neuro-Oncology 2019, 21: 1493-1494. PMID: 31777936, PMCID: PMC6917408, DOI: 10.1093/neuonc/noz193.
• ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USEWeller M, Reardon D, Brandes A, Sampson J, Mulholland P, Wick A, Baehring J, Ahluwalia M, Roth P, Bähr O, Phuphanich S, Sepulveda J, de Souza P, Sahebjam S, Potter V, Tatsuoka K, Taitt C, Zwirtes R, Omuro A, Lim M. ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE Neuro-Oncology 2019, 21: vi12-vi12. PMCID: PMC6847600, DOI: 10.1093/neuonc/noz175.045.
• Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantationCorrea DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation Journal Of Neuro-Oncology 2019, 144: 553-562. PMID: 31377920, PMCID: PMC7392129, DOI: 10.1007/s11060-019-03257-1.
• Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatmentsFrank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang X, Vacic V, Bergmann EA, Moore Vogel JL, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Correction to: Sequencing and curation strategies for identifying candidate glioblastoma treatments BMC Medical Genomics 2019, 12: 114. PMID: 31375115, PMCID: PMC6676607, DOI: 10.1186/s12920-019-0563-y.
• Sequencing and curation strategies for identifying candidate glioblastoma treatmentsFrank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Sequencing and curation strategies for identifying candidate glioblastoma treatments BMC Medical Genomics 2019, 12: 56. PMID: 31023376, PMCID: PMC6485090, DOI: 10.1186/s12920-019-0500-0.
• Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. American Journal Of Hematology 2019, 94: 455-460. PMID: 30663807, DOI: 10.1002/ajh.25414.
• Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR ImagingThulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging Clinical Cancer Research 2019, 25: 1226-1232. PMID: 30487127, PMCID: PMC7462306, DOI: 10.1158/1078-0432.ccr-18-2079.
• Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II TrialWen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial Journal Of Clinical Oncology 2019, 37: jco.18.01207. PMID: 30715997, PMCID: PMC6553812, DOI: 10.1200/jco.18.01207.
• Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSamstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D’Angelo S, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nature Genetics 2019, 51: 202-206. PMID: 30643254, PMCID: PMC6365097, DOI: 10.1038/s41588-018-0312-8.
• RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIBArmstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology 2018, 20: vi241-vi241. PMCID: PMC6217700, DOI: 10.1093/neuonc/noy148.998.
• Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaTun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O’Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma Blood 2018, 132: 2240-2248. PMID: 30262659, PMCID: PMC6265643, DOI: 10.1182/blood-2018-02-835496.
• P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumabPentsova E, Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Boire A, DeAngelis L, Raizer J. P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab Neuro-Oncology 2018, 20: iii304-iii304. PMCID: PMC6144227, DOI: 10.1093/neuonc/noy139.336.
• Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal Of Clinical Oncology 2018, 36: 1702-1709. PMID: 29683790, PMCID: PMC5993168, DOI: 10.1200/jco.2017.76.9992.
• In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine. Radiology 2018, 287: 667-675. PMID: 29388903, PMCID: PMC5929369, DOI: 10.1148/radiol.2017162610.
• Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumabThomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab CNS Oncology 2018, 07: 7-13. PMID: 29388793, PMCID: PMC6001559, DOI: 10.2217/cns-2017-0025.
• Overall survival in patients with glioblastoma before and after bevacizumab approvalJohnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval Current Medical Research And Opinion 2017, 34: 813-820. PMID: 29025274, DOI: 10.1080/03007995.2017.1392294.
• CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENTMalani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. CMET-04. CEREBROSPINAL FLUID CIRCULATING TUMOR CELLS (CSF CTC) FOR PATIENT MONITORING AND RESPONSE TO TREATMENT Neuro-Oncology 2017, 19: vi39-vi39. PMCID: PMC5692986, DOI: 10.1093/neuonc/nox168.153.
• Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 Neuro-Oncology 2017, 20: 674-686. PMID: 29106665, PMCID: PMC5892140, DOI: 10.1093/neuonc/nox208.
• 325O Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)Lim M, Omuro A, Vlahovic G, Reardon D, Sahebjam S, Cloughesy T, Baehring J, Butowski N, Potter V, Zwirtes R, Paliwal P, Carleton M, Sampson J, Brandes A. 325O Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM) Annals Of Oncology 2017, 28: v109. DOI: 10.1093/annonc/mdx366.
• Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaGrommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma Cancer Discovery 2017, 7: 1018-1029. PMID: 28619981, PMCID: PMC5581705, DOI: 10.1158/2159-8290.cd-17-0613.
• Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsZehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nature Medicine 2017, 23: 1004-1004. PMID: 28777785, DOI: 10.1038/nm0817-1004c.
• Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic AstrocytomaClarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma International Journal Of Radiation Oncology • Biology • Physics 2017, 99: 797-804. PMID: 28870792, PMCID: PMC5654655, DOI: 10.1016/j.ijrobp.2017.06.2466.
• Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumorsLin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors Neuro-Oncology 2017, 19: 1248-1254. PMID: 28821205, PMCID: PMC5570249, DOI: 10.1093/neuonc/nox066.
• Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Briggs S, DeAngelis L, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. Journal Of Clinical Oncology 2017, 35: 11549-11549. DOI: 10.1200/jco.2017.35.15_suppl.11549.
• NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).Galanis E, Anderson S, Butowski N, Hormigo A, Schiff D, Tran D, Omuro A, Jaeckle K, Kumar S, Kaufmann T, Buckner J, Twohy E, Giannini C, Wen P. NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance). Journal Of Clinical Oncology 2017, 35: 2023-2023. DOI: 10.1200/jco.2017.35.15_suppl.2023.
• Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2017, 35: 7515-7515. DOI: 10.1200/jco.2017.35.15_suppl.7515.
• Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL).Tun H, Johnston P, Grommes C, Reeder C, Omuro A, Menke D, Copland J, DeAngelis L, Witzig T. Phase I clinical trial on pomalidomide and dexamethasone in treating patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL). Journal Of Clinical Oncology 2017, 35: 7516-7516. DOI: 10.1200/jco.2017.35.15_suppl.7516.
• OncoKB: A Precision Oncology Knowledge BaseChakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base JCO Precision Oncology 2017, 2017: 1-16. PMID: 28890946, PMCID: PMC5586540, DOI: 10.1200/po.17.00011.
• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsZehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Nature Medicine 2017, 23: 703-713. PMID: 28481359, PMCID: PMC5461196, DOI: 10.1038/nm.4333.
• Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendrogliomaThomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma Neuro-Oncology 2017, 19: 1380-1390. PMID: 28472509, PMCID: PMC5596171, DOI: 10.1093/neuonc/nox086.
• OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Zwirtes R, Sampson J. OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143 Neuro-Oncology 2017, 19: iii13-iii13. PMCID: PMC5463686, DOI: 10.1093/neuonc/nox036.044.
• OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143Reardon D, Omuro A, Brandes A, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia M, Lim M, Vlahovic G, Sampson J. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 Neuro-Oncology 2017, 19: iii21-iii21. PMCID: PMC5463583, DOI: 10.1093/neuonc/nox036.071.
• Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastasesHatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.
• Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomasNayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas Journal Of Neuro-Oncology 2017, 132: 181-188. PMID: 28116649, PMCID: PMC5588922, DOI: 10.1007/s11060-016-2357-9.
• "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A. "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply. Neuro-Oncology 2016, 19: 301-302. PMID: 28040711, PMCID: PMC5464186, DOI: 10.1093/neuonc/now286.
• Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology 2016, 19: 422-429. PMID: 27994065, PMCID: PMC5464299, DOI: 10.1093/neuonc/now238.
• Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS LymphomaLin X, Lee M, Buck O, Woo K, Zhang Z, Hatzoglou V, Omuro A, Arevalo-Perez J, Thomas A, Huse J, Peck K, Holodny A, Young R. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma American Journal Of Neuroradiology 2016, 38: 485-491. PMID: 27932505, PMCID: PMC5352508, DOI: 10.3174/ajnr.a5023.
• Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System LymphomaGrommes C, Pastore A, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma Blood 2016, 128: 783-783. DOI: 10.1182/blood.v128.22.783.783.
• ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Strauss L, Latek R, Zwirtes R, Paliwal P, Harbison C, Sampson J. ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143 Neuro-Oncology 2016, 18: vi21-vi21. DOI: 10.1093/neuonc/now212.081.
• RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG)Zukas A, Bennani N, Chou C, Johnston P, O’Neill B, Nijland M, Batchelor T, Nayak L, Mrugala M, Low J, Omuro A, Ferreri A, Nishikawa R, Mishima K, Fox C, Wilson W, Houillier C, Chamberlain M, Schiff D. RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG) Neuro-Oncology 2016, 18: vi168-vi168. DOI: 10.1093/neuonc/now212.702.
• ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. ACTR-12. PHASE I/II STUDY OF SINGLE AGENT IBRUTINIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL) Neuro-Oncology 2016, 18: vi3-vi4. DOI: 10.1093/neuonc/now212.011.
• MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIALKuhn J, Chen R, Clarke J, Chang S, Cloughesy T, Colman H, Wen P, Mellinghoff I, Ligon K, Groot J, Batchelor T, Omuro A, Taylor J, Butowski N, Halperin R, Tran N, Carpten J, Craig D, Byron S, Berens M, Prados M. MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL Neuro-Oncology 2016, 18: vi105-vi105. DOI: 10.1093/neuonc/now212.440.
• A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide ConditioningScordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Transplantation And Cellular Therapy 2016, 23: 38-43. PMID: 27713090, PMCID: PMC5518313, DOI: 10.1016/j.bbmt.2016.09.024.
• Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I TrialXu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial Clinical Cancer Research 2016, 22: 4786-4796. PMID: 27154916, PMCID: PMC5050072, DOI: 10.1158/1078-0432.ccr-16-0048.
• 331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, Deangelis L. 331PD Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) Annals Of Oncology 2016, 27: vi105. DOI: 10.1093/annonc/mdw367.09.
• Long-term survival in AIDS-related primary central nervous system lymphomaGupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma Neuro-Oncology 2016, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.
• Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2016, 34: 2468-77. PMID: 27269943, PMCID: PMC4962737, DOI: 10.1200/JCO.2015.65.7825.
• Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer careHatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care Cancer 2016, 122: 2708-2714. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.
• Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.Reardon D, Sampson J, Sahebjam S, Lim M, Baehring J, Vlahovic G, Cloughesy T, Strauss L, Latek R, Paliwal P, Harbison C, Voloschin A, Omuro A. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. Journal Of Clinical Oncology 2016, 34: 2014-2014. DOI: 10.1200/jco.2016.34.15_suppl.2014.
• Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).Grommes C, Kaley T, Nolan C, Omuro A, Wolfe J, Mellinghoff I, DeAngelis L. Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2016, 34: 2046-2046. DOI: 10.1200/jco.2016.34.15_suppl.2046.
• Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).Omuro A, Beal K, McNeill K, Thomas A, Lin X, Kaley T, DeAngelis L, Mellinghoff I, Diamond E, Chan T, Young R, Yamada Y, Gorman G, Lamson M, Bavisotto L, Karmali R. Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2016, 34: 2060-2060. DOI: 10.1200/jco.2016.34.15_suppl.2060.
• Overall survival in patients with glioblastoma before and after bevacizumab approval.Johnson D, Omuro A, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Macalalad A, Shi S, Uhm J. Overall survival in patients with glioblastoma before and after bevacizumab approval. Journal Of Clinical Oncology 2016, 34: 2062-2062. DOI: 10.1200/jco.2016.34.15_suppl.2062.
• Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG).Lin X, Kaley T, Pentsova E, DeAngelis L, Daras M, Gavrilovic I, Mellinghoff I, McKeown A, Manne M, Hansen J, Bavisotto L, Gorman G, Lamson M, Karmali R, Omuro A. Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG). Journal Of Clinical Oncology 2016, 34: 2064-2064. DOI: 10.1200/jco.2016.34.15_suppl.2064.
• A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.Sampson J, Omuro A, Preusser M, Lim M, Butowski N, Cloughesy T, Strauss L, Latek R, Paliwal P, Weller M, Reardon D. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Journal Of Clinical Oncology 2016, 34: tps2079-tps2079. DOI: 10.1200/jco.2016.34.15_suppl.tps2079.
• Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidPentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid Journal Of Clinical Oncology 2016, 34: 2404-2415. PMID: 27161972, PMCID: PMC4981784, DOI: 10.1200/jco.2016.66.6487.
• Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease ControlNguyen D, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V. Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control Ophthalmology 2016, 123: 2047-2050. PMID: 27137876, DOI: 10.1016/j.ophtha.2016.03.043.
• Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) ConditioningScordo M, Bhatt V, Hsu M, Omuro A, Matasar M, DeAngelis L, Dahi P, Moskowitz C, Giralt S, Sauter C. Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning Transplantation And Cellular Therapy 2016, 22: s132-s133. DOI: 10.1016/j.bbmt.2015.11.465.
• High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous systemCurry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system Leukemia & Lymphoma 2016, 57: 1961-1964. PMID: 26727454, DOI: 10.3109/10428194.2015.1120867.
• Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant gliomade la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma Neuro-Oncology 2015, 18: 283-290. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.
• A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiationHatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation Neuro-Oncology 2015, 18: 873-880. PMID: 26688076, PMCID: PMC4864262, DOI: 10.1093/neuonc/nov301.
• Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS LymphomaChristian G, Thomas K, Abdel-Wahab O, Omuro A, Ingo M, DeAngelis L. Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma Blood 2015, 126: 3960-3960. DOI: 10.1182/blood.v126.23.3960.3960.
• Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS LymphomaBhatt V, Scordo M, Hsu M, Omuro A, DeAngelis L, Lin A, Matasar M, Dahi P, Moskowitz C, Giralt S, Sauter C. Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma Blood 2015, 126: 1994-1994. DOI: 10.1182/blood.v126.23.1994.1994.
• A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) ConditioningScordo M, Bhatt V, Hsu M, Omuro A, Matasar M, DeAngelis L, Dahi P, Moskowitz C, Giralt S, Sauter C. A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning Blood 2015, 126: 4354-4354. DOI: 10.1182/blood.v126.23.4354.4354.
• NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143Ramkissoon S, Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Latek R, Vandeloise E, Coric V, Cloughesy T, Lim M, Reardon D, Ligon K. NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 Neuro-Oncology 2015, 17: v156-v157. PMCID: PMC4639040, DOI: 10.1093/neuonc/nov225.17.
• NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143)Omuro A, Baehring J, Sahebjam S, Vlahovic G, Voloschin A, Young R, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Sampson J, Reardon D. NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143) Neuro-Oncology 2015, 17: v157-v157. PMCID: PMC4639041, DOI: 10.1093/neuonc/nov225.18.
• NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717)Sahebjam S, Omuro A, Baehring J, Sampson J, Vlahovic G, Voloschin A, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Reardon D. NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717) Neuro-Oncology 2015, 17: v156-v156. PMCID: PMC4639039, DOI: 10.1093/neuonc/nov225.16.
• QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143Nayak L, Brandes A, Omuro A, Rieger J, Wick A, Phuphanich S, Sumrall A, Sahebjam S, Ahluwalia M, de Souza P, Sepulveda J, Maio M, Grauer O, Vlahovic G, Baehring J, Dastani H, Latek R, Coric V, Reardon D. QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143 Neuro-Oncology 2015, 17: v189-v189. PMCID: PMC4639164, DOI: 10.1093/neuonc/nov230.07.
• CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143Lowther D, Weinhold K, Reap E, Vlahovic G, Omuro A, Sahebjam S, Baehring J, Voloschin A, Cloughesy T, Lim M, Coric V, Latek R, Simon J, Lerner B, Raddassi K, Hafler D, Sampson J. CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143 Neuro-Oncology 2015, 17: v70-v70. PMCID: PMC4638710, DOI: 10.1093/neuonc/nov211.06.
• IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143Sampson J, Omuro A, Vlahovic G, Sahebjam S, Baehring J, Hafler D, Voloschin A, Simon J, Latek R, Coric V, Cloughesy T, Lim M, Reardon D. IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143 Neuro-Oncology 2015, 17: v107-v107. PMCID: PMC4638899, DOI: 10.1093/neuonc/nov218.03.
• Patterns of Salvage Treatment for High Grade Glioma in Patients Who Received Upfront TemozolomideEscorcia F, Spratt D, Folkert M, Zumsteg Z, Chan T, Omuro A, Gutin P, Yamada Y, Beal K. Patterns of Salvage Treatment for High Grade Glioma in Patients Who Received Upfront Temozolomide International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e113-e114. DOI: 10.1016/j.ijrobp.2015.07.837.
• Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyButowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study Neuro-Oncology 2015, 18: 557-564. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.
• Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancerNayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer Cancer 2015, 121: 4165-4172. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.
• Clinical ReasoningFaivre G, Pentsova E, Demopoulos A, Taillibert S, Rosenblum M, Omuro A. Clinical Reasoning Neurology 2015, 85: e57-e61. PMID: 26283762, PMCID: PMC4548283, DOI: 10.1212/wnl.0000000000001848.
• Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trialOmuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio M, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy M, Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial The Lancet Haematology 2015, 2: e251-e259. PMID: 26688235, DOI: 10.1016/s2352-3026(15)00074-5.
• Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade gliomaWen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma Neuro-Oncology 2015, 17: 1275-1283. PMID: 26019185, PMCID: PMC4588757, DOI: 10.1093/neuonc/nov083.
• Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Hafler D, Voloschin A, Paliwal P, Grosso J, Coric V, Cloughesy T, Lim M, Reardon D. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. Journal Of Clinical Oncology 2015, 33: 3010-3010. DOI: 10.1200/jco.2015.33.15_suppl.3010.
• Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Tanguy M, Omuro A, Hoang-Xuan K. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. Journal Of Clinical Oncology 2015, 33: 2035-2035. DOI: 10.1200/jco.2015.33.15_suppl.2035.
• Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT AssayOmuro A, Zehir A, Cheng D, Berger M, Hyman D, Solit D, Baselga J, Ladanyi M, Arcila M, Hameed M, Sabbatini P, DeAngelis L, Gutin P, Rosenblum M, Mellinghoff I, Tabar V, Chan T, Briggs S, Huse J, Brennan C. Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay Journal Of Clinical Oncology 2015, 33: 2057-2057. DOI: 10.1200/jco.2015.33.15_suppl.2057.
• Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).Thomas A, Beal K, McNeill K, Kaley T, DeAngelis L, Mellinghoff I, Diamond E, Chan T, Young R, Arevalo Perez J, Yamada Y, Anderson B, Lamson M, Burch B, Karmali R, Omuro A. Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2015, 33: 2062-2062. DOI: 10.1200/jco.2015.33.15_suppl.2062.
• Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.Lin X, Fleisher M, Omuro A, Shagabayeva L, Pentsova E. Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors. Journal Of Clinical Oncology 2015, 33: 2072-2072. DOI: 10.1200/jco.2015.33.15_suppl.2072.
• Detection of cerebral spinal fluid (CSF) circulating melanoma cells (CMC) for the diagnosis of melanoma leptomeningeal metastasis (LM).Lin X, Fleisher M, Shagabayeva L, Omuro A, Pentsova E. Detection of cerebral spinal fluid (CSF) circulating melanoma cells (CMC) for the diagnosis of melanoma leptomeningeal metastasis (LM). Journal Of Clinical Oncology 2015, 33: e13061-e13061. DOI: 10.1200/jco.2015.33.15_suppl.e13061.
• Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status.Dunphy M, Harding J, Lewis J, Mellinghoff I, Omuro A, Hsieh J, Zhang H, Zanzonico P, Venneti S, Carlin S, Younes A, Gerecitano J, Lyashchenko S, Harris L, Lashley A, Kung H, Thompson C, Kelsen D. Phenotypic correlation of tumor uptake of exogenous glutamine radiotracer versus tumor mutational status. Journal Of Clinical Oncology 2015, 33: 11014-11014. DOI: 10.1200/jco.2015.33.15_suppl.11014.
• First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysisKasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.
• Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivoVenneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo Science Translational Medicine 2015, 7: 274ra17. PMID: 25673762, PMCID: PMC4431550, DOI: 10.1126/scitranslmed.aaa1009.
• Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic EvidencePrager A, Martinez N, Beal K, Omuro A, Zhang Z, Young R. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence American Journal Of Neuroradiology 2015, 36: 877-885. PMID: 25593202, PMCID: PMC4731220, DOI: 10.3174/ajnr.a4218.
• R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphomaOmuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma Blood 2015, 125: 1403-1410. PMID: 25568347, PMCID: PMC4342354, DOI: 10.1182/blood-2014-10-604561.
• Emerging Therapies for GlioblastomaThomas AA, Brennan CW, DeAngelis LM, Omuro AM. Emerging Therapies for Glioblastoma JAMA Neurology 2014, 71: 1437-1444. PMID: 25244650, DOI: 10.1001/jamaneurol.2014.1701.
• AT-07A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIALArmstrong T, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. AT-07A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL Neuro-Oncology 2014, 16: v9-v9. PMCID: PMC4217844, DOI: 10.1093/neuonc/nou237.7.
• AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASESRaizer J, Pentsova E, Omuro A, Lin N, Nayak L, Quant E, Kumthekar P. AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES Neuro-Oncology 2014, 16: v19-v19. PMCID: PMC4217826, DOI: 10.1093/neuonc/nou237.46.
• AT-35INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIALLassman A, Grommes C, Panageas K, Iwamoto F, DeAngelis L, Kaley T, Gavrilovic I, Pentsova E, Omuro A, Corpuz C, Briggs S, Otap D, Qin W, Cross J, Mellinghoff I. AT-35INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL Neuro-Oncology 2014, 16: v16-v16. PMCID: PMC4217814, DOI: 10.1093/neuonc/nou237.35.
• AI-09PATTERNS OF SALVAGE TREATMENT FOR HIGH GRADE GLIOMA IN THE TEMOZOLOMIDE ERAEscorcia F, Folkert M, Spratt D, Zumsteg Z, Chan T, Omuro A, Beal K, Gutin P, Yamada J. AI-09PATTERNS OF SALVAGE TREATMENT FOR HIGH GRADE GLIOMA IN THE TEMOZOLOMIDE ERA Neuro-Oncology 2014, 16: v3-v3. PMCID: PMC4217875, DOI: 10.1093/neuonc/nou238.9.
• TM-15GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVOVenneti S, Dunphy M, Zhang H, Pitter K, Campos C, Carlin S, Lyashchenko S, Plöessl C, Rohle D, Omuro A, Cross J, Brennan C, Weber W, Holland E, Mellinghoff I, Kung H, Lewis J, Thompson C. TM-15GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO Neuro-Oncology 2014, 16: v216-v216. PMCID: PMC4218624, DOI: 10.1093/neuonc/nou278.14.
• AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIALGilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology 2014, 16: v13-v13. PMCID: PMC4217801, DOI: 10.1093/neuonc/nou237.23.
• NI-57DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE PERFUSION WEIGHTED IMAGING (DCE-MRI) AND DIFFUSION WEIGHTED IMAGING (DWI) FOR PHARMACODYNAMIC EVALUATION OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) AND TEMOZOLOMIDE IN MALIGNANT GLIOMAMagge R, Perez J, Young R, Kaley T, Pentsova E, DeAngelis L, Diamond E, Mellinghoff I, Peck K, Anderson B, Gorman G, Mclean S, Karmali R, Omuro A. NI-57DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE PERFUSION WEIGHTED IMAGING (DCE-MRI) AND DIFFUSION WEIGHTED IMAGING (DWI) FOR PHARMACODYNAMIC EVALUATION OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) AND TEMOZOLOMIDE IN MALIGNANT GLIOMA Neuro-Oncology 2014, 16: v150-v151. PMCID: PMC4218384, DOI: 10.1093/neuonc/nou264.55.
• Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed GlioblastomaOmuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma Clinical Cancer Research 2014, 20: 5023-5031. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.ccr-14-0822.
• Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression From Radiation Injury After Cranial IrradiationYang T, Young R, Hatzoglou V, Ulaner G, Schneider T, Omuro A, Chan T, Yamada Y, Beal K. Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression From Radiation Injury After Cranial Irradiation International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s164. DOI: 10.1016/j.ijrobp.2014.05.660.
• Advanced MR and PET Imaging Characteristics of an Intra-Axial Brain SchwannomaBerry N, Thakur S, Hatzoglou V, Rosenblum M, Omuro A, Holodny A. Advanced MR and PET Imaging Characteristics of an Intra-Axial Brain Schwannoma Neurographics 2014, 4: 123-128. DOI: 10.3174/ng.3140088.
• Current Role of Anti-Angiogenic Strategies for GlioblastomaThomas AA, Omuro A. Current Role of Anti-Angiogenic Strategies for Glioblastoma Current Treatment Options In Oncology 2014, 15: 551-566. PMID: 25173555, DOI: 10.1007/s11864-014-0308-2.
• Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsVera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients Neuro-Oncology 2014, 17: 440-447. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.
• Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningiomaKaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma Neuro-Oncology 2014, 17: 116-121. PMID: 25100872, PMCID: PMC4483051, DOI: 10.1093/neuonc/nou148.
• PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUMWen P, Wen P, Yung W, Mellinghoff I, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro A, DeAngelis L, Gilbert M, DeGroot J, Cloughesy T, Lee E, Nayak L, Chi A, Batchelor T, Chang S, Prados M, Reardon D, Ligon K. PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM Neuro-Oncology 2014, 16: iii47-iii47. PMCID: PMC4144634, DOI: 10.1093/neuonc/nou209.20.
• Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamideWelch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, Omuro AM. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide Leukemia & Lymphoma 2014, 56: 361-367. PMID: 24745937, DOI: 10.3109/10428194.2014.916800.
• Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.Wen P, Yung W, Mellinghoff I, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro A, DeAngelis L, Gilbert M, De Groot J, Cloughesy T, Chi A, Lee E, Nayak L, Batchelor T, Chang S, Prados M, Reardon D, Ligon K. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. Journal Of Clinical Oncology 2014, 32: 2019-2019. DOI: 10.1200/jco.2014.32.15_suppl.2019.
• A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.Butowski N, Colman H, De Groot J, Omuro A, Nayak L, Cloughesy T, Marimuthu A, Perry A, Phillips J, West B, Prados M, Nolop K, Hsu H, Ligon K. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. Journal Of Clinical Oncology 2014, 32: 2023-2023. DOI: 10.1200/jco.2014.32.15_suppl.2023.
• Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.Omuro A, Kaley T, Pentsova E, DeAngelis L, Urba W, Taylor M, Anderson B, Gorman G, McLean S, Karmali R. Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways. Journal Of Clinical Oncology 2014, 32: 2071-2071. DOI: 10.1200/jco.2014.32.15_suppl.2071.
• Transcriptional diversity of long-term glioblastoma survivorsGerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors Neuro-Oncology 2014, 16: 1186-1195. PMID: 24662514, PMCID: PMC4136896, DOI: 10.1093/neuonc/nou043.
• Methotrexate re-challenge for recurrent primary central nervous system lymphomaPentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.
• Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene AmplificationGupta A, Young R, Shah A, Schweitzer A, Graber J, Shi W, Zhang Z, Huse J, Omuro A. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification Clinical Neuroradiology 2014, 25: 143-150. PMID: 24474262, PMCID: PMC4712066, DOI: 10.1007/s00062-014-0289-3.
• Glioblastoma and Other Malignant Gliomas: A Clinical ReviewOmuro A, DeAngelis LM. Glioblastoma and Other Malignant Gliomas: A Clinical Review JAMA 2013, 310: 1842-1850. PMID: 24193082, DOI: 10.1001/jama.2013.280319.
• Primary leptomeningeal lymphomaTaylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, DeAngelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma Neurology 2013, 81: 1690-1696. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.
• Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term OutcomeMorris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome Journal Of Clinical Oncology 2013, 31: 3971-3979. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/jco.2013.50.4910.
• Bevacizumab for acute neurologic deterioration in patients with glioblastomaKaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.
• Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with GlioblastomaYoung R, Gupta A, Shah A, Graber J, Schweitzer A, Prager A, Shi W, Zhang Z, Huse J, Omuro A. Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma American Journal Of Neuroradiology 2013, 34: 2271-2277. PMID: 23811973, PMCID: PMC4712068, DOI: 10.3174/ajnr.a3604.
• Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study.Cloughesy T, Mischel P, Omuro A, Prados M, Wen P, Wu B, Rockich K, Xu Y, Lager J, Mellinghoff I. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. Journal Of Clinical Oncology 2013, 31: 2012-2012. DOI: 10.1200/jco.2013.31.15_suppl.2012.
• Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).Wen P, Yung W, Mellinghoff I, Lamborn K, Ramkissoon S, Cloughesy T, Rinne M, Omuro A, DeAngelis L, Gilbert M, Chi A, Batchelor T, Colman H, Chang S, Massacesi C, DiTomaso E, Prados M, Reardon D, Ligon K. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Journal Of Clinical Oncology 2013, 31: 2015-2015. DOI: 10.1200/jco.2013.31.15_suppl.2015.
• Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire J, Benouaich Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, Sierra del Rio M, Gonzalez A, Houillier C, Tanguy M, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study. Journal Of Clinical Oncology 2013, 31: 2032-2032. DOI: 10.1200/jco.2013.31.15_suppl.2032.
• Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.Huse J, Beal K, Zhang J, Kastenhuber E, Kaley T, Abrey L, Gutin P, Brennan C, Omuro A. Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses. Journal Of Clinical Oncology 2013, 31: 2057-2057. DOI: 10.1200/jco.2013.31.15_suppl.2057.
• Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).Kaley T, Pentsova E, Omuro A, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis L, Lacouture M, Holland E, Lassman A. Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG). Journal Of Clinical Oncology 2013, 31: 2095-2095. DOI: 10.1200/jco.2013.31.15_suppl.2095.
• A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.Sandler A, Taylor M, Urba W, Omuro A, Anderson B, Hansen D, Fisher B, Claeys A, Greathouse A, McLean S, Karmali R. A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2518-2518. DOI: 10.1200/jco.2013.31.15_suppl.2518.
• Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumorsNayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, DeAngelis LM, Omuro A. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors Neurology 2013, 80: 1598-1605. PMID: 23553479, PMCID: PMC3662321, DOI: 10.1212/wnl.0b013e31828f183f.
• Histology and Anatomic Site in EpendymomaRaghunathan A, Wani K, Armstrong TS, Vera‐Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito‐Reyes M, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD, Network C. Histology and Anatomic Site in Ependymoma Brain Pathology 2013, 23: 584-594. PMID: 23452038, PMCID: PMC8028973, DOI: 10.1111/bpa.12050.
• Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC MeasurementsGupta A, Prager A, Young R, Shi W, Omuro A, Graber J. Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements American Journal Of Neuroradiology 2012, 34: e10-e11. PMID: 23275590, PMCID: PMC4724797, DOI: 10.3174/ajnr.a3467.
• Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant gliomaOmuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, DeAngelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma Neuro-Oncology 2012, 15: 242-250. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.
• First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-AnalysisKasenda B, Ferreri A, Maturano E, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Xuan K, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Gloy V, Bhatnagar N, Haug S, Rahner S, Illerhaus G, Briel M. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis Blood 2012, 120: 3655-3655. DOI: 10.1182/blood.v120.21.3655.3655.
• Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer CenterWelch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.
• Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphomaNayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, Consortium F. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma Leukemia & Lymphoma 2012, 54: 58-61. PMID: 22656234, PMCID: PMC4802006, DOI: 10.3109/10428194.2012.698736.
• New Treatments for Leptomeningeal Metastases Are Urgently NeededMorris P, Omuro A. New Treatments for Leptomeningeal Metastases Are Urgently Needed Journal Of Thoracic Oncology 2012, 7: 1204. DOI: 10.1097/jto.0b013e3182598d49.
• MRI perfusion in determining pseudoprogression in patients with glioblastomaYoung RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z, Shi W, Beal K, Omuro AM. MRI perfusion in determining pseudoprogression in patients with glioblastoma Clinical Imaging 2012, 37: 41-49. PMID: 23151413, PMCID: PMC4755513, DOI: 10.1016/j.clinimag.2012.02.016.
• Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast CancerMorris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.
• Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome.Curry R, Correa D, Raizer J, Grimm S, Lai R, Schiff D, Grant B, Reiner A, Panageas K, Yahalom J, DeAngelis L, Abrey L, Morris P, Omuro A. Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. Journal Of Clinical Oncology 2012, 30: 2006-2006. DOI: 10.1200/jco.2012.30.15_suppl.2006.
• Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL).Omuro A, Correa D, Moskowitz C, Matasar M, DeAngelis L, Kaley T, Gavrilovic I, Nolan C, Pentsova E, Grommes C, Abrey L, Sauter C. Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal Of Clinical Oncology 2012, 30: 2008-2008. DOI: 10.1200/jco.2012.30.15_suppl.2008.
• Bevacizumab for recurrent WHO grade III anaplastic glioma (AG).Delios A, Brennan C, Huse J, Colevas K, Omuro A. Bevacizumab for recurrent WHO grade III anaplastic glioma (AG). Journal Of Clinical Oncology 2012, 30: 2028-2028. DOI: 10.1200/jco.2012.30.15_suppl.2028.
• High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma.Welch M, Sauter C, Matasar M, Moskowitz C, Omuro A. High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma. Journal Of Clinical Oncology 2012, 30: 2089-2089. DOI: 10.1200/jco.2012.30.15_suppl.2089.
• Atypical and anaplastic meningiomas treated with bevacizumabNayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.
• Primary Central Nervous System LymphomasGraber J, Omuro A. Primary Central Nervous System Lymphomas 2012, 125-133. DOI: 10.1002/9781118321478.ch12.
• Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosisPentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis Leukemia & Lymphoma 2012, 53: 1620-1622. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.
• A prognostic gene expression signature in infratentorial ependymomaWani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K, For the Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma Acta Neuropathologica 2012, 123: 727-738. PMID: 22322993, PMCID: PMC4013829, DOI: 10.1007/s00401-012-0941-4.
• Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain RadiotherapyMorris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.
• Chapter 58 Complications of radiotherapy to the central nervous systemOmuro AM, Martin-Duverneuil N, Delattre JY. Chapter 58 Complications of radiotherapy to the central nervous system 2012, 105: 887-901. PMID: 22230540, DOI: 10.1016/b978-0-444-53502-3.00030-6.
• Primary central nervous system lymphomaGraber JJ, Omuro A. Primary central nervous system lymphoma Current Opinion In Neurology 2011, 24: 633-640. PMID: 21968551, DOI: 10.1097/wco.0b013e32834cbdef.
• A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progressionMason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D. A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression Journal Of Neuro-Oncology 2011, 107: 343-349. PMID: 22048878, DOI: 10.1007/s11060-011-0747-6.
• Cognitive functions in primary CNS lymphoma after single or combined modality regimensCorrea DD, Shi W, Abrey LE, DeAngelis LM, Omuro AM, Deutsch MB, Thaler HT. Cognitive functions in primary CNS lymphoma after single or combined modality regimens Neuro-Oncology 2011, 14: 101-108. PMID: 22013168, PMCID: PMC3245999, DOI: 10.1093/neuonc/nor186.
• Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisitedGupta A, Omuro AM, Shah AD, Graber JJ, Shi W, Zhang Z, Young RJ. Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited Neuroradiology 2011, 54: 641-643. PMID: 22006425, PMCID: PMC4724213, DOI: 10.1007/s00234-011-0970-z.
• Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)Beal K, Omuro A, Karimi S, Correa D, Chan T, DeAngelis L, Yamada Y, Abrey L, Gutin P. Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM) International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s129. DOI: 10.1016/j.ijrobp.2011.06.266.
• Temozolomide for low-grade gliomasKaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard M, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon J, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre J, Hoang-Xuan K. Temozolomide for low-grade gliomas Neurology 2011, 77: 263. DOI: 10.1212/01.wnl.0000400061.70034.aa.
• Prophylactic intrathecal chemotherapy in primary CNS lymphomaSierra del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma Journal Of Neuro-Oncology 2011, 106: 143-146. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.
• Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapyMorris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy Leukemia & Lymphoma 2011, 52: 1891-1897. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.
• Pharmacotherapy for Primary CNS LymphomaGraber JJ, Omuro A. Pharmacotherapy for Primary CNS Lymphoma CNS Drugs 2011, 25: 447-457. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.
• Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastomaYoung R, Gupta A, Shah A, Graber J, Zhang Z, Shi W, Holodny A, Omuro A. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma Neurology 2011, 76: 1918-1924. PMID: 21624991, PMCID: PMC3115805, DOI: 10.1212/wnl.0b013e31821d74e7.
• Magnetic resonance (MR) perfusion imaging to differentiate early progression from pseudoprogression following chemoradiotherapy for glioblastoma (GBM).Graber J, Young R, Gupta A, Shah A, Chan T, Zhang Z, Shi W, Beal K, Omuro A. Magnetic resonance (MR) perfusion imaging to differentiate early progression from pseudoprogression following chemoradiotherapy for glioblastoma (GBM). Journal Of Clinical Oncology 2011, 29: 2009-2009. DOI: 10.1200/jco.2011.29.15_suppl.2009.
• Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma (PCNSL).Pentsova E, DeAngelis L, Omuro A. Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma (PCNSL). Journal Of Clinical Oncology 2011, 29: 2025-2025. DOI: 10.1200/jco.2011.29.15_suppl.2025.
• Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).Omuro A, Beal K, Karimi S, Correa D, Chan T, DeAngelis L, Gavrilovic I, Nolan C, Hormigo A, Lassman A, Kaley T, Mellinghoff I, Grommes C, Panageas K, Reiner A, Barradas R, Abrey L, Gutin P. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2011, 29: 2028-2028. DOI: 10.1200/jco.2011.29.15_suppl.2028.
• Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01.Nayak L, Abrey L, Drappatz J, Gilbert M, Reardon D, Lamborn K, Wen P, Prados M, DeAngelis L, Omuro A. Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. Journal Of Clinical Oncology 2011, 29: 2039-2039. DOI: 10.1200/jco.2011.29.15_suppl.2039.
• Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma.De Groot J, Cloughesy T, Lieberman F, Chang S, Omuro A, Drappatz J, Batchelor T, DeAngelis L, Gilbert M, Yung W, Fisher J, Ye X, Lamborn K, Chen A, Grossman S, Prados M, Wen P. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. Journal Of Clinical Oncology 2011, 29: 2043-2043. DOI: 10.1200/jco.2011.29.15_suppl.2043.
• FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM).Grommes C, Karimi S, Beal K, Chan T, Abrey L, Gutin P, Omuro A. FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM). Journal Of Clinical Oncology 2011, 29: 2048-2048. DOI: 10.1200/jco.2011.29.15_suppl.2048.
• CMV encephalitis in BMT recipientsSarva H, Graber J, Remanan R, Rosenblum M, Omuro A. CMV encephalitis in BMT recipients Bone Marrow Transplantation 2011, 47: 318-320. PMID: 21460874, DOI: 10.1038/bmt.2011.80.
• Targeted Therapy for Malignant GliomasDankwah-Quansah M, Omuro A. Targeted Therapy for Malignant Gliomas 2011, 299-307. DOI: 10.1007/978-94-007-0344-5_31.
• Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?Omuro A, Taillandier L, Chinot O, Sierra del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K, On behalf of the ANOCEF Group (French Neuro-Oncology Association).. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? Journal Of Neuro-Oncology 2010, 104: 323-330. PMID: 21170569, DOI: 10.1007/s11060-010-0497-x.
• Neurological Complications of Non-Hodgkin LymphomaKhasraw M, Noy A, Gilbert M, Omuro A. Neurological Complications of Non-Hodgkin Lymphoma 2010, 267-285. DOI: 10.1007/978-1-4419-7668-0_16.
• Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytomaDucray F, Sierra del Rio M, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma Journal Of Neuro-Oncology 2010, 101: 457-462. PMID: 20556480, DOI: 10.1007/s11060-010-0264-z.
• Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).Nayak L, Fleisher M, Gonzalez-Espinoza R, Reiner A, Panageas K, Lin O, Liu C, DeAngelis L, Omuro A. Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST). Journal Of Clinical Oncology 2010, 28: 2032-2032. DOI: 10.1200/jco.2010.28.15_suppl.2032.
• Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).Omuro A, Beal K, Karimi S, Chan T, Panageas K, Nayak L, Seko B, DeAngelis L, Abrey L, Gutin P. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2010, 28: 2036-2036. DOI: 10.1200/jco.2010.28.15_suppl.2036.
• Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL).Morris P, Abrey L, Reiner A, Panageas K, Seko B, DeAngelis L, Omuro A. Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL). Journal Of Clinical Oncology 2010, 28: 2040-2040. DOI: 10.1200/jco.2010.28.15_suppl.2040.
• Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).Khasraw M, Abrey L, Lassman A, Hormigo A, Nolan C, Gavrilovic I, Mellinghoff I, Reiner A, DeAngelis L, Omuro A. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). Journal Of Clinical Oncology 2010, 28: 2065-2065. DOI: 10.1200/jco.2010.28.15_suppl.2065.
• A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression.Mason W, Belanger K, Nicholas G, Vallieres I, Mathieu D, Desjardins A, Kavan P, Omuro A, Reymond D. A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression. Journal Of Clinical Oncology 2010, 28: 2094-2094. DOI: 10.1200/jco.2010.28.15_suppl.2094.
• A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.Nghiemphu P, Omuro A, Cloughesy T, Mellinghoff I, Norden A, Nguyen L, Rajangam K, Wen P. A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. Journal Of Clinical Oncology 2010, 28: 3085-3085. DOI: 10.1200/jco.2010.28.15_suppl.3085.
• Bevacizumab and irinotecan (BI) for gliomatous leptomeningeal disease.Taillibert S, Guillevin R, Dehais C, Bellanger A, Omuro A. Bevacizumab and irinotecan (BI) for gliomatous leptomeningeal disease. Journal Of Clinical Oncology 2010, 28: e12526-e12526. DOI: 10.1200/jco.2010.28.15_suppl.e12526.
• Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients.Omuro A, Taillandier L, Chinot O, Ghesquieres H, Soussain C, Delwail V, Choquet S, Tanguy M, Lamy T, Hoang-Xuan K. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine (PCB), vincristine (VINC), and cytarabine (Ara-C) for primary CNS lymphoma (PCNSL) in elderly patients. Journal Of Clinical Oncology 2010, 28: tps144-tps144. DOI: 10.1200/jco.2010.28.15_suppl.tps144.
• Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomideKaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide Journal Of Neuro-Oncology 2010, 100: 439-441. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.
• Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancerDe Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer Journal Of Neuro-Oncology 2010, 100: 443-447. PMID: 20440540, PMCID: PMC3246379, DOI: 10.1007/s11060-010-0200-2.
• Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant gliomaWen P, Omuro A, Batchelor T, Lai A, Mellinghoff I, Nghiemphu L, Norden A, Gendreau S, Laird A, Nguyen L, Cloughesy T. Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma Molecular Cancer Therapeutics 2009, 8: b265-b265. DOI: 10.1158/1535-7163.targ-09-b265.
• Antiangiogenic Strategies for the Treatment of GliomasBazzoli E, Omuro A. Antiangiogenic Strategies for the Treatment of Gliomas 2009, 243-263. DOI: 10.1007/978-1-4419-0410-2_12.
• Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experienceDankwah-Quansah M, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey L, DeAngelis L, Omuro A. Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience Journal Of Clinical Oncology 2009, 27: e13011-e13011. DOI: 10.1200/jco.2009.27.15_suppl.e13011.
• Exploring multi-targeting strategies for the treatment of gliomas.Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Current Opinion In Investigational Drugs (London, England : 2000) 2008, 9: 1287-95. PMID: 19037835.
• What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-719. PMID: 18989118, DOI: 10.1097/wco.0b013e3283184625.
• Primary CNS lymphoma with intraocular involvementGrimm S, McCannel C, Omuro A, Ferreri A, Blay J, Neuwelt E, Siegal T, Batchelor T, Jahnke K, Shenkier T, Hall A, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto F, Abrey L. Primary CNS lymphoma with intraocular involvement Neurology 2008, 71: 1355-1360. PMID: 18936428, PMCID: PMC4109164, DOI: 10.1212/01.wnl.0000327672.04729.8c.
• Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie CellulaireSoussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire Journal Of Clinical Oncology 2008, 26: 2512-2518. PMID: 18413641, DOI: 10.1200/jco.2007.13.5533.
• What is the relevance of determining EGFR-variant-III status in glioblastomas?Omuro AM. What is the relevance of determining EGFR-variant-III status in glioblastomas? Nature Clinical Practice. Oncology 2008, 5: 188-9. PMID: 18319741, DOI: 10.1038/ncponc1074.
• Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, investigators O. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882) European Journal Of Cancer 2008, 44: 1210-1216. PMID: 18248979, DOI: 10.1016/j.ejca.2007.12.005.
• Brain tumors and dementiaOmuro AM, Delattre J. Brain tumors and dementia 2008, 89: 877-886. PMID: 18631803, DOI: 10.1016/s0072-9752(07)01277-8.
• Editorial: what is new in the treatment of gliomas?Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-707. PMID: 17992093, DOI: 10.1097/wco.0b013e3282f1beef.
• A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastasesIwamoto FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT, Abrey LE. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases Journal Of Neuro-Oncology 2007, 87: 85-90. PMID: 17987262, DOI: 10.1007/s11060-007-9491-3.
• Molecular genetic markers as predictors of response to chemotherapy in gliomasIdbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas Current Opinion In Oncology 2007, 19: 606-611. PMID: 17906460, DOI: 10.1097/cco.0b013e3282f075f3.
• Temozolomide and methotrexate for primary central nervous system lymphoma in the elderlyOmuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly Journal Of Neuro-Oncology 2007, 85: 207-211. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.
• Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group ReportGrimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.
• Is single-agent temozolomide the treatment of choice for recurrent primary central nervous system lymphoma?Omuro AM. Is single-agent temozolomide the treatment of choice for recurrent primary central nervous system lymphoma? Nature Clinical Practice. Oncology 2007, 4: 514-5. PMID: 17622233, DOI: 10.1038/ncponc0898.
• Lessons learned in the development of targeted therapy for malignant gliomasOmuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas Molecular Cancer Therapeutics 2007, 6: 1909-1919. PMID: 17620423, DOI: 10.1158/1535-7163.mct-07-0047.
• A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastasesIwamoto F, Omuro A, Raizer J, Nolan C, Hormigo A, Lassman A, Gavrilovic I, Abrey L. A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases Journal Of Clinical Oncology 2007, 25: 2050-2050. DOI: 10.1200/jco.2007.25.18_suppl.2050.
• Temozolomide for low-grade gliomasKaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard M, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon J, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre J, Hoang-Xuan K. Temozolomide for low-grade gliomas Neurology 2007, 68: 1831-1836. PMID: 17515545, DOI: 10.1212/01.wnl.0000262034.26310.a2.
• Dynamic history of low‐grade gliomas before and after temozolomide treatmentRicard D, Kaloshi G, Amiel‐Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle‐Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang‐Xuan K, Delattre J. Dynamic history of low‐grade gliomas before and after temozolomide treatment Annals Of Neurology 2007, 61: 484-490. PMID: 17469128, DOI: 10.1002/ana.21125.
• Chemotherapy for primary central nervous system lymphoma.Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical FOCUS 2006, 21: e12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.
• Pitfalls in the diagnosis of brain tumours.Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. The Lancet. Neurology 2006, 5: 937-48. PMID: 17052661, DOI: 10.1016/S1474-4422(06)70597-X.
• Chemoradiotherapy for primary CNS lymphomaOmuro A, Yahalom J, Abrey L. Chemoradiotherapy for primary CNS lymphoma Progress In Neurotherapeutics And Neuropsychopharmacology 2006, 2: 123-136. DOI: 10.1017/s1748232106000097.
• Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred?Omuro A, Taillandier L, Chinot O, Carnin C, Barrie M, Soussain C, Leblond V, Hoang-Xuan K. Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred? Journal Of Clinical Oncology 2006, 24: 1551-1551. DOI: 10.1200/jco.2006.24.18_suppl.1551.
• Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trialOmuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial Journal Of Neuro-Oncology 2006, 78: 277-280. PMID: 16614943, DOI: 10.1007/s11060-005-9095-8.
• Ventriculoperitoneal shunt in patients with leptomeningeal metastasisChamberlain M, Glantz M, DeAngelis L, Omuro A, Lallana E, Bilsky M. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis Neurology 2006, 66: 783. PMID: 16534138, DOI: 10.1212/01.wnl.0000205135.85388.01.
• Hypersexuality following bilateral thalamic infarction: case reportMutarelli EG, Omuro AM, Adoni T. Hypersexuality following bilateral thalamic infarction: case report Arquivos De Neuro-Psiquiatria 2006, 64: 146-148. PMID: 16622574, DOI: 10.1590/s0004-282x2006000100032.
• Salvage temozolomide for prior temozolomide respondersFranceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders Cancer 2005, 104: 2473-2476. PMID: 16270316, DOI: 10.1002/cncr.21564.
• Delayed Neurotoxicity in Primary Central Nervous System LymphomaOmuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.
• High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibOmuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 2005, 103: 2344-2348. PMID: 15844174, DOI: 10.1002/cncr.21033.
• Ventriculoperitoneal shunt in patients with leptomeningeal metastasisOmuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis Neurology 2005, 64: 1625-1627. PMID: 15883329, DOI: 10.1212/01.wnl.0000160396.69050.dc.
• EGFR tyrosine kinase domain mutations in human gliomasMarie Y, Carpentier A, Omuro A, Sanson M, Thillet J, Hoang-Xuan K, Delattre J. EGFR tyrosine kinase domain mutations in human gliomas Neurology 2005, 64: 1444-1445. PMID: 15851741, DOI: 10.1212/01.wnl.0000158654.07080.b0.
• Chemoradiotherapy for primary CNS lymphomaOmuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.wnl.0000148641.98241.5e.
• A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastasesOmuro A, Raizer J, Abrey L. A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastases Journal Of Clinical Oncology 2004, 22: 1567-1567. DOI: 10.1200/jco.2004.22.14_suppl.1567.
• A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastasesOmuro A, Raizer J, Abrey L. A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastases Journal Of Clinical Oncology 2004, 22: 1567-1567. DOI: 10.1200/jco.2004.22.90140.1567.
• Brain metastasesOmuro AM, Abrey LE. Brain metastases Current Neurology And Neuroscience Reports 2004, 4: 205-210. PMID: 15102346, DOI: 10.1007/s11910-004-0040-6.